Schettini, Francesco http://orcid.org/0000-0001-6561-1919
Chic, Nuria
Brasó-Maristany, Fara
Paré, Laia http://orcid.org/0000-0002-4904-558X
Pascual, Tomás http://orcid.org/0000-0001-8431-3183
Conte, Benedetta
Martínez-Sáez, Olga
Adamo, Barbara
Vidal, Maria http://orcid.org/0000-0003-1992-5727
Barnadas, Esther
Fernández-Martinez, Aranzazu
González-Farre, Blanca
Sanfeliu, Esther
Cejalvo, Juan Miguel
Perrone, Giuseppe
Sabarese, Giovanna
Zalfa, Francesca
Peg, Vicente
Fasani, Roberta
Villagrasa, Patricia
Gavilá, Joaquín
Barrios, Carlos H. http://orcid.org/0000-0001-6021-667X
Lluch, Ana http://orcid.org/0000-0003-2766-407X
Martín, Miguel
Locci, Mariavittoria
De Placido, Sabino
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI16/00904)
Breast Cancer Now (2018NOVPCC1294)
PhD4MD
Sociedad Española de Oncología Médica
Article History
Received: 30 April 2020
Accepted: 13 November 2020
First Online: 4 January 2021
Change Date: 29 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-023-00538-x
Competing interests
: A.P. has declared an immediate family member being employed by Novartis, personal honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly and Daiichi Sankyo, travel, accommodations and expenses paid by Daiichi Sankyo, research funding from Roche and Novartis, consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer and Bristol-Myers Squibb, and patent PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY. C.B. declares research funding, consulting and honoraria form Astra Zeneca, Novartis, Roche, GSK, Pfizer, Libbs, Daiichi Sankyo, and MSD. A.L. declares clinical research fundings from Amgen, Astra Zeneca, Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Celgene, Pierre Fabre and advisory boards and consulting for Novartis, Pfizer, Roche/Genentech, Eisai, Celgene. M.M. declares research grants from Roche, PUMA and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer and speakers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis and Pfizer. J.G. has declared speakers’ honoraria and participation in advisory boards from Pfizer, Roche, and Novartis. S.D.P. has declared honoraria from Roche, Pfizer, Astra-Zeneca, Novartis, Celgene, Eli Lilly, Amgen, and Eisai. The other authors have nothing to declare.